吉非替尼治疗晚期非小细胞肺癌临床疗效分析

Clinical efficacy analysis of Gefitinib in the treatment of non-small cell lung cancer

目的:观察吉非替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:15例晚期NSCLC患者口服吉非替尼250mg/d,直到疾病进展或不可耐受的毒副反应停药。结果:本组15例晚期NSCLC患者经治疗后,无CR病例,6例PR(40.0%),5例SD(33.3%),4例PD(26.7%)。总的疾病控制率(CR+PR+SD)为73.3%。全组15例病例中,8例(53.3%)在服药1周后出现Ⅰ/Ⅱ度皮疹。2例(13.3%)发生Ⅰ、Ⅱ度腹泻,1例(6.7%)发生Ⅲ度腹泻;1例(6.7%)出现Ⅱ度谷丙转氨酶(AI)升高。15例患者未见肺纤维化,亦未见心、肝、肾功能损害等毒副作用。结论:口服吉非替尼单药对于经放化疗治疗失败的晚期非小细胞肺癌,是一种有效且具有良好耐受性的治疗方案。

Objective： To observe the clinical efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： 15 cases of advanced NSCLC patients with oral C, efitinib 250 mg/day until disease progression or non-tolerance drug toxicity occured. Results： After treatment, no CR cases, six cases of PR（40.0%）, 5 cases of SD（33.3%）, 4 cases of PD （26.7%）. The overall disease control rate （CR＋PR＋SD） was 73.3%. Among all 15 cases, rash of I/II degree occured in 8 cases（53.3%） one week after the medication, I/II degree severe diarrhea occurred in 2 cases（13.3%）, III degrees diarrhea occurred in one eases（6.7%）;II degree Gubing transaminase（AI） increased in 1 cases（6.7%）.NO pulmonary fibrosis occurred,no heart, liver, renal dysfunction and other side effects. Conclusion： Oral Gefitinib mono-therapy is effective and has good tolerability in the treatment of NSCLC patients for which the chemicotherapy failed.